Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis - Join Clinical Trial NCTNCT05485961
How to Join This Clinical Trial - NCTNCT05485961
Learn how to participate in this PHASE2, PHASE3 trial studying an investigational therapy for Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD. This study is currently enrolling participants.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE2, PHASE3 - Large-scale efficacy study
- Enrollment Status
- Currently enrolling participants
- Study Identifier
- NCTNCT05485961 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 346 locations. Find a study site near you:
Clinical Research Site
Huntsville, Alabama 35805 - United States
Status: RECRUITING
Clinical Research Site
Montgomery, Alabama 36117 - United States
Status: RECRUITING
Clinical Research Site
Glendale, Arizona 85305 - United States
Status: RECRUITING
Clinical Research Site
Glendale, Arizona 91206 - United States
Status: RECRUITING
Clinical Research Site
Phoenix, Arizona 85018 - United States
Status: RECRUITING
Clinical Research Site
Tucson, Arizona 85705 - United States
Status: RECRUITING
Clinical Research Site
Bakersfield, California 93309 - United States
Status: RECRUITING
Clinical Research Site
Bakersfield, California 93309 - United States
Status: RECRUITING
Clinical Research Site
Beverly Hills, California 90211 - United States
Status: RECRUITING
Clinical Research Site
Chula Vista, California 91910 - United States
Status: RECRUITING
And 336 more locations available. Contact us to find the nearest participating site.
How to Enroll in This Study
To learn more about participating in this PHASE2, PHASE3 clinical trial for Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD:
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships